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E-mail address: ozcengiz@metu.edu.tr (G. ÖzcengiPasteurella multocida serotype A:3 is a Gram-negative bacterial pathogen, one of the causative agents of
shipping fever of cattle. In this study, outer membrane protein H (ompH) and Pasteurella lipoprotein E
(plpE) genes were cloned and plpEC-ompH fusion was constructed and expressed in Escherichia coli.
Recombinant PlpE, OmpH and PlpEC-OmpH fusion proteins were puriﬁed and formulated with oil-based
and oil-based CpG ODN adjuvants. Antibody responses in mice vaccinated with recombinant PlpE and
PlpEC-OmpH proteins formulated with both adjuvants were signiﬁcantly (p < 0.05) increased. However,
a signiﬁcant (p < 0.05) increment in serum IFN-c level was only observed upon immunization with oil-
based CpG formulations. Protectivity of the vaccines were evaluated via intraperitoneal challenge of mice
with 10 LD50 of P. multocida A:3. The recombinant proteins PlpE and PlpEC-OmpH fusion conferred 100%
protection when formulated with oil-based CpG ODNwhile the protectivity was found to be 80% and 60%,
respectively when only oil-based adjuvant was used in respective formulations. These ﬁndings indicated
that the recombinant PlpE or PlpEC-OmpH fusion proteins formulated with oil-based CpG ODN adjuvant
are possible acellular vaccine candidates against shipping fever.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Bovine respiratory diseases (BRDs) are one of the most serious
problems in the cattle industry causing high mortality and eco-
nomic loss. BRDs are associated with stressful conditions, such as
commingling and shipment of cattle, and adverse climatic condi-
tions coupled with bacterial and viral infections. Pasteurella multo-
cida is a facultative intracellular bacterial pathogen associated with
the clinical syndromes of the BRD complex including neonatal calf
(enzootic) pneumonia and beef cattle pneumonia (shipping fever).
Infections by P. multocida serogroup A are responsible for severe
bronchopneumonia in young dairy calves, and the majority of
samples from affected cattle have been found to be positive for
P. multocida serotype A:3 (Dabo et al., 2008b).
Currently available P. multocida cattle vaccines are predomi-
nately traditional bacterins and a live streptomycin-dependent
(STRD) mutant (Dabo et al., 2008b). These vaccines have some lim-
itations such as being serotype-speciﬁc (Catt et al., 1985) or confer-
ring partial protection (Mathy et al., 2002). Moreover, Dowling
et al. (2004) reported that intratracheal vaccination of calves withll rights reserved.
: +90 312 2107976.
z).formalin-killed P. multocida did not result in protection against
experimental pulmonary challenge. Inactivated vaccines are gener-
ally ineffective at inducing a potent cell-mediated immune re-
sponse which is important in the elimination of intracellular
pathogens (Singh and O’Hagan, 2002). Commercial vaccines
against BRD are monovalent or divalent, limiting their efﬁcacy. Re-
cent studies have focused on multivalent vaccines containing anti-
genic proteins to simplify the vaccination schedule and increase
the protection range (Cho et al., 2008) as well as genetic fusions
to deliver diverse antigens to the immune system (Ayalew et al.,
2008). On the other hand, a proper adjuvant plays an important
role in the success of the vaccine formulations containing recombi-
nant proteins (Buchman et al., 2010).
Recent studies have shown that several P. multocida outer mem-
brane proteins (OMPs) contributed to the pathogenesis and pos-
sess immunogenic and bactericidal properties (Basagoudanavar
et al., 2006; Lee et al., 2007; Tan et al., 2010). OmpH is an antigenic,
surface-exposed and conserved OMP porin that is detected in 100%
of bovine isolates investigated and has been mooted as a potential
vaccine candidate (Dabo et al., 2008b). Pasteurella lipoprotein E
(PlpE) is another immunogenic OMP of P. multocida and mice or
chickens immunized with recombinant PlpE were protected
against challenge with other P. multocida serotypes (Wu et al.,
2007). To date, protection conferred by recombinant PlpE and
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been investigated.
The aim of the present study was to investigate the efﬁcacy of
the recombinant PlpE, OmpH and PlpEC-OmpH proteins from P.
multocida A:3, one of the causative agents of shipping fever, in a
mouse model. The recombinant proteins were formulated with
oil-based or oil-based CpG ODN adjuvants and inoculated into
BALB/c mice. Protectivity of the formulations was evaluated by sur-
vival of the mice upon challenge with a lethal dose of the pathogen.
Our data indicated that rPlpE or rPlpEC-OmpH formulated with an
oil-based CpG ODN conferred 100% survival against 10 LD50 of P.
multocida in mice.2. Materials and methods
2.1. Bacterial strains and plasmids
Escherichia coli DH5a (ATCC) and E. coli BL21 (Novagen, Ger-
many) were the bacterial hosts for cloning and expression of the
genes from P. multocida P-1062 (ATCC 15743, serotype A:3). The
cloning vector pGEMT Easy (Promega, USA) and expression vector
pET28a(+) (Novagen, Germany) were used.
2.2. Construction of recombinant plasmids
plpE and ompH genes were ampliﬁed via PCR using chromo-
somal DNA of P. multocida P-1062. The plpE gene was ampliﬁed
with PlpEF: ggatccatgtgtagcggtggtgg (BamHI) and PlpER: agat-
ctttgtgcttggtgactt (BglII) primers. Primers for the C-terminal frag-
ment were PlpECF: ggatccatgccttcagcagattacaa (BamHI) and
PlpER. The ompH gene was ampliﬁed with OmpHF: agat-
ctatggcaacagtttacaa (BglII) and OmpHR: agatctttagaagtgtacgcgta
(BglII) primers. PCR products were ligated to pGEMT Easy vector
and introduced into E. coli DH5a. The pGEMT-plpEC and pGEMT-
ompH plasmids were cut with BglII and the ompH fragment was li-
gated to pGEMT-plpEC to obtain plpEC-ompH fusion. Recombinant
plasmids were veriﬁed with restriction enzyme digestion and
nucleotide sequence analysis. The genes were subsequently cloned
in pET28a to express His-tagged proteins (pET28-plpE, pET28-
ompH and pET28-plpEC-ompH).
2.3. Puriﬁcation of recombinant proteins and preparation of vaccine
formulations
E. coli BL21 cells carrying pET28-plpEC-ompH, pET28-plpE and
pET28-ompH were grown in Luria Broth (LB; Merck, Germany)
supplemented with 30 lg of kanamycin/ml. Expression was in-
duced at OD600 of 0.6 by adding isopropyl-b-D-galactopyranoside
(IPTG; Sigma, Germany) to 1 mM ﬁnal concentration and incubated
at 37 C for 5 h in a shaker incubator at 200 rpm. Cells were har-
vested by centrifugation and resuspended in LEW buffer (8 M urea,
300 mM NaCl, 50 mM NaH2PO4, pH 8.0). Following the sonication
using a CP70T Ultrasonic Processor (Cole-Parmer, USA) for
6  10 s at 60% amplitude, cellular debris was removed by centri-
fugation. The supernatants containing the recombinant proteins
were puriﬁed on Protino Ni-TED 2000 packed columns (Mache-
rey–Nagel, Germany) according to the supplier’s recommenda-
tions. Eluted proteins were dialyzed against DB buffer (50 mM
NaH2PO4, 500 mM NaCl, 4 M urea, pH 8.0) and sterilized through
a 0.2 lm membrane ﬁlter. The purity of proteins was determined
by SDS–PAGE. The recombinant proteins were formulated with
oil based (Montanide ISA 206 VG, Seppic, France) or oil based-
CpG ODN 1555 adjuvant. The sequence of a phosphorothiote mod-
iﬁed, 15-mer CpG 1555 is reported elsewhere (Gursel et al., 2001).
Ten microgram of CpG ODN was used per dose.2.4. Immunization and challenge experiments
Female BALB/c mice weighing 16–18 g were used in animal
experiments. 100 lg of recombinant PlpE, OmpH and PlpEC-OmpH
proteins formulated with the oil-based or oil-based CpG ODN adju-
vant were intraperitoneally (IP) inoculated into mice at days 0 and
21 and the mice were challenged at day 31. Mice in the two paral-
lel control groups received either oil-based or oil-based CpG ODN
adjuvant only. The mice were tail bled a day prior to both booster
vaccination and challenge (days 20 and 30, respectively). The sera
were maintained at 20 C until further use. Animals were chal-
lenged IP with 10 LD50 of P. multocida A:3 (55 CFU) in 500 ll of sal-
ine solution. Survivors were recorded daily for seven days. Animal
experiments were performed under the approval of the Ethics
Committee on Animal Experimentation, Middle East Technical Uni-
versity, Turkey.
2.5. Western blot analysis
Recombinant proteins were run on 12% SDS–polyacrylamide gel
and transferred to nitrocellulose membranes by a modiﬁedmethod
of Towbin et al. (1979) using a semi-dry blotting system (Cleaver
Scientiﬁc Ltd, UK). Each lane for rPlpE, rOmpH and PlpEC-OmpH
was separated cutting the nitrocellulose membrane. Western blot
analysis was carried out using the respective primary antibodies
raised against rPlpE, rOmpH or PlpEC-OmpH fusion proteins at
day 30 post primary vaccination at a dilution of 1:200. Rabbit
anti-mouse IgG conjugated to alkaline phosphatase (Sigma, Ger-
many) was used as the secondary antibody at a dilution of
1:10,000. AP Conjugate Substrate Kit (Bio-Rad, USA) was used for
color detection. PageRuler™ Plus Prestained Protein Ladder (Fer-
mentas, Thermo Scientiﬁc, USA) was used as the size marker.
2.6. Determination of antibody response to vaccine formulations
Speciﬁc antibody response was determined measuring the IgG
titers via ELISA using sera collected from vaccinated mice. Puriﬁed
recombinant PlpE, OmpH and PlpEC-OmpH proteins were used as
coating antigens at concentrations of 1 lg/well for determination
of anti-PlpE, anti-OmpH and anti-PlpEC-OmpH antibody levels,
respectively. Two-fold serial dilutions of the murine sera ranging
from 1:100 to 1:12800 were used in triplicates as primary antibody
and rabbit anti-mouse IgG conjugated to alkaline phosphatase
(Sigma, Germany) was used as secondary antibody at a dilution
of 1:2000. PNPP substrate (p-Nitrophenyl Phosphate Disodium
Salt, Therno Scientiﬁc, USA) was used as colorimetric reagent.
Plates were read at 405 nm to determine optical density on a
microtiter plate reader.
2.7. ELISA for detection of serum IFN-c titers
Mouse IFN-c Minikit (Pierce, Thermo Scientiﬁc, USA) was used
for the detection of serum IFN-c levels of vaccinated mice. The pro-
tocol was applied according to the manufacturer’s recommenda-
tions. Brieﬂy, 96-well plates were coated with Coating Antibody
and blocked with Blocking Buffer. Serum samples were added at
1:4 dilutions in Assay Buffer and incubated at RT overnight. After
washing the plate, Detection Antibody was added to each well
and incubated 1 h at RT. The plate was washed and Streptavidin-
HRP (Pierce, Thermo Scientiﬁc, USA) was added at a dilution of
1:10,000. The plate was incubated at RT for 30 min and washed.
TMB substrate (Pierce, Thermo Scientiﬁc, USA) was added to each
well and incubated at RT for 30 min. The reaction was stopped with
0.18 M sulphuric acid and the absorbance read at 450 nm on a
microtiter plate reader. The ng values were extrapolated from a
ng vs absorbance curve for a set of standards on the plates.
Fig. 1. SDS–polyacrylamide gel (A) and Western blot (B) analyses of the rPlpE
protein (lane 1), rOmpH protein (lane 2) and PlpEC-OmpH fusion protein (lane 3).
M: protein molecular weight marker. Western blot analysis was performed cutting
nitrocellulose membrane for each lane and using anti-rPlpE, anti-rOmpH and anti-
PlpEC-OmpH sera collected at day 30 as primary antibodies for lanes 1, 2 and 3,
respectively.
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An analysis of variance (ANOVA) and the Tukey’s test were used
for mean comparison of antibody response between groups.Fig. 2. Serum IgG titers in mice vaccinated with rPlpE, rOmpH and PlpEC-OmpH formula
plates with rPlpE, rOmpH and PlpEC-OmpH fusion protein, respectively. 1:100 to 1:128
vaccination, at day 30 (B) were used and averages of triplicate samples were represente
Fig. 3. Serum IFN-c responses in mice vaccinated with rPlpE, rOmpH and PlpEC-OmpH fo
using 1:4 dilution of the sera collected after ﬁrst vaccination (at day 20) and booster vacc
for a set of standards on the plates. ⁄indicates statistical difference (p < 0.05) between cSurvival data were compared using the chi-square test (two-sided).
Statistical analyses for immune responses and survival were per-
formed using GraphPad Prism version 5.00 for Windows (Graph-
Pad Software, USA). The signiﬁcance level (p) for all analyses was
set at 0.05. Standard deviations were calculated using Microsoft
Ofﬁce Excel 2010 program.3. Results
3.1. Cloning of plpE and ompH genes from P. multocida A:3
and puriﬁcation of the recombinant proteins
plpE gene (936 bp) without signal sequence, 459 bp C-terminal
(plpEC) fragment and 969 bp ompH gene were cloned via PCR from
the genomic DNA of P. multocida A:3 and the sequences were ver-
iﬁed. In this study, the C-terminal of PlpE was used to obtain chi-
meric protein with OmpH since it was determined to be more
immunogenic as compared to an N-terminal fragment (Okay
et al., unpublished data). plpE, ompH and plpEC-ompH were cloned
in pET28a for His-tagged protein expression. The purity of the re-
combinant proteins was visualized on SDS–polyacrylamide gel by
Coomassie blue staining and antigenicity was shown by Western
blot analysis (Fig. 1). Puriﬁed recombinant OmpH and PlpEC-OmpH
proteins had bands with expected molecular masses of 37 and
54 kDa, respectively on SDS–polyacrylamide gels. rPlpE proteinted with oil-based and oil-based CpG ODN adjuvant measured by ELISA coating the
00 dilutions of the sera collected after ﬁrst vaccination, at day 20 (A) and booster
d with standard deviations.
rmulated with oil-based (A) or oil-based CpG ODN (B) adjuvant measured by ELISA
ination (at day 30). The ng values were extrapolated from a ng vs absorbance curve
ontrol and vaccinated groups.
Table 1
Protection conferred in BALB/c mice vaccinated IP with 100 lg of rPlpE, rOmpH and
rPlpEC-OmpH proteins formulated with oil-based or oil-based CpG ODN adjuvants,
respectively upon IP challenge with 10 LD50 of live P. multocida A:3.
Vaccine formulation (protein/
adjuvant)
No. of mice survived/
challenged
Protection
(%)
rPlpE/oil-based 4/5 80*
rPlpE/oil-based CpG 5/5 100*
rOmpH/oil-based 2/5 40
rOmpH/oil-based CpG 2/5 40
PlpEC-OmpH/oil-based 3/5 60*
PlpEC-OmpH/oil-based CpG 5/5 100*
Control (oil-based adjuvant) 0/5 0
Control (oil based CpG adjuvant) 0/5 0
* Statistically signiﬁcant as compared to control group, p < 0.05.
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(data not shown) and the eluate, while its calculated mass was
36.5 kDa, indicating its processing in E. coli. Western blot analysis
using speciﬁc antibodies showed that these antibodies reacted
with puriﬁed recombinant protein antigens.3.2. Immune responses against PlpE, OmpH and PlpEC-OmpH proteins
and their protective efﬁcacies
BALB/c mice were inoculated IP twice with 100 lg of rPlpE,
rOmpH and PlpEC-OmpH proteins formulated with oil-based and
oil-based CpG ODN adjuvants. The sera were collected prior to both
booster inoculation and challenge (days 20 and 30, respectively)
and used for the measurement of IgG titers and IFN-c levels. As
shown in Fig. 2, serum IgG levels in mice vaccinated with rPlpE
and rPlpEC-OmpH signiﬁcantly (p < 0.05) increased after ﬁrst and
second immunizations. On the other hand, the increment in IgG le-
vel upon injection with rOmpH formulated with oil-based or oil-
based CpG ODN was only signiﬁcant after second vaccination and
at lower dilutions.
Serum IFN-c levels in mice IP vaccinated with rPlpE, rOmpH and
PlpEC-OmpH formulated with oil-based and oil-based CpG ODN
adjuvants were determined by ELISA (Fig. 3). Oil-based CpG ODN
adjuvanted formulations signiﬁcantly (p < 0.05) increased serum
IFN-c titers after ﬁrst and second vaccinations while the increment
was not statistically signiﬁcant with oil-based adjuvant alone.
The protective efﬁcacy of rPlpE, rOmpH and PlpEC-OmpH pro-
teins formulated with oil-based or oil-based CpG ODN adjuvants
was investigated after IP challenge of the immunized mice with
10 LD50 of live P. multocida A:3 (Table 1, Fig. 4). Vaccine formula-
tions composed of rPlpE with oil-based or oil-based CpG ODN con-
ferred 80% and 100% protection, respectively. Protectivity of
rPlpEC-OmpH fusion proteins formulated with oil-based or oil-
based CpG ODN was 60% and 100%, respectively. However,Fig. 4. Kaplan Meier survival curves of mice (n = 5) immunized with rPlpE, rOmpH and P
adjuvants upon IP challenge with 10 LD50 of live P. multocida A:3.formulations containing rOmpH provided 40% protection, not sta-
tistically signiﬁcant.4. Discussion
Outer membrane protein H (OmpH) and Pasteurella lipoprotein
E (PlpE) are of interest in recombinant vaccine studies against dif-
ferent serotypes of P. multocida. Wu et al. (2007) reported that
rPlpE fromP. multocida serotype A:1 causing fowl cholera conferred
63–100% protection in mice and chickens against challenge with
serotypes A:1, A:3 and A:4. Luo et al. (1997) vaccinated chickens
with native and recombinant OmpH from P. multocida serotype
A:1 and reported 100% and 18% protection, respectively. However,
Sthitmatee et al. (2008) showed that both native and recombinant
OmpH from serotype A:1 and its identical protein, Cp39 from sero-
type A:3, conferred 60–100% protection in chickens against chal-
lenge with serotypes A:1 and A:3. Tan et al. (2010) immunized
mice IP and subcutaneously with rOmpH from P. multocida sero-
type B:2 causing haemorrhagic septicaemia and obtained 80%
and 100% protection, respectively. Moreover, rOmpH fromP. multo-
cida isolated from a case of atrophic rhinitis provided 70% protec-
tion in mice (Lee et al., 2007). Dabo et al. (2008a) vaccinated
mice with rOmpA from a bovine isolate of P. multocida serotype
A:3 but no protection was obtained. Till now, there has been no re-
port on protectivity of rPlpE or rOmpH proteins isolated from P.
multocida A:3 causing shipping fever. In the present study, we
showed that rPlpE, rOmpH and PlpEC-OmpH fusion proteins pro-
vided 80–100%, 40% and 60–100% homologous protection, respec-
tively depending on the adjuvant used in the formulation. A cross-
protection experiment was not performed in this study since the
only P. multocida serotype involved in shipping fever is A:3.
Selection of appropriate adjuvants that boost antigen immuno-
genicity is one of the critical steps in vaccine development (Rojo-
Montejo et al., 2011). CpG ODNs have been utilized as vaccine
adjuvants in studies on animals because they induce Th1-type cell
mediated immunity, as evidenced by increased IFN-c through
binding to TLR9, which is involved in the recognition of patho-
gen-associated molecular patterns (Klinman et al., 2004). Oil-based
adjuvants (emulsions) have been used in vaccine formulations
since 1945 (Aucouturier et al., 2006). Montanide ISA 206 is a safe
water-in-oil-in-water emulsion commonly used in vaccine studies
against animal pathogens including P. multocida (Basagoudanavar
et al., 2006; Dupuis et al., 2006). It has been shown that CpG
ODN in combination with Montanide ISA 206 synergistically in-
duced higher immune responses to VP1 antigen of FMDV in mice
and cattle as compared to an either CpG ODN or Montanide only
formulation (Ren et al., 2011). Consistently, our study showed that
Montanide plus CpG ODN adjuvanted formulations induced both
IgG and serum IFN-c in vaccinated mice whilst Montanide only
formulations did not increase serum IFN-c. The control group mice
were inoculated with oil-based CpG ODN adjuvant alone. The high-lpEC-OmpH fusion protein formulated with (A) oil-based or (B) oil-based CpG ODN
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to that in control group showed that the increase in IFN-c titers
was antigen-speciﬁc. Still, the use of splenocyte cultures stimu-
lated with the antigen for the detection of IFN-c levels would pro-
vide convincing evidence.
Our study constitutes the ﬁrst recombinant vaccination strategy
utilizing PlpE and OmpH against P. multocida A:3, demonstrating
that rPlpE or PlpEC-OmpH fusion proteins conferred 100% survival
in mice when injected together with Montanide modiﬁed-CpG
ODN, and our further work will involve the trials of vaccination
in cattle using these formulations.
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